Licensing Opportunity: Intranasal Ebola Vaccine

 Licensing Opportunity:

Intranasal Ebola Vaccine

Colorized scanning electron micrograph of filamentous Ebola virus particles (yellow) attached to and budding from a chronically infected VERO E6 cell (red) (25,000x magnification). Image captured and color-enhanced at the NIAID Integrated Research Facility in Ft. Detrick, Maryland. Credit: NIAID

Ebola virus is transmitted by contact with body fluids from infected individuals. Aerosolized Ebola virus could also be exploited for intentional virus spread. Vaccines that protect against mucosal and systematic exposure are needed. NIAID researchers have developed an attenuated and immunogenic intranasal vaccine candidate against Ebola that is expected to be well tolerated in humans and is available for clinical evaluation.

Read more about this exciting licensing opportunity: https://www.ott.nih.gov/technology/e-142-2018-0.